• P. N. Patsalos


Gabapentin (Fig. 1) corresponds chemically to 1-(aminomethyl)-cyclohexaneacetic acid with an empirical formula of C9H17NO2 and a molecular weight of 171.23.


Valproic Acid Empirical Formula Therapeutic Drug Monitoring Renal Excretion Drug Monitoring 


  1. 1.
    Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 1994;35:155–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationships of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis. CNS Drugs. 2012;26:79–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Sachdeo R. Lacosamide. In: Shorvon SD, Perucca E, Engel J, ­editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing. 2009:527-34.Google Scholar
  4. 4.
    Perucca E, Baltes E, Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs). Epilepsia. 2000;41(Suppl):150.Google Scholar
  5. 5.
    Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol. 1991;31:171–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Graves NM, Holmes GB, Leppik IE, et al. Pharmacokinetics of gabapentin in patients treated with phenytoin. Pharmacotherapy. 1989;9:196.Google Scholar
  7. 7.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 (Suppl 6):13–18.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations